Synthetic CAR Libraries May Aid Immunotherapy Development
Over the past decade, substantial progress has been made in modern immunotherapy, driven by targeted therapies that inhibit tumor angiogenesis and intrinsic drivers of cancer-cell growth.
Over the past decade, substantial progress has been made in modern immunotherapy, driven by targeted therapies that inhibit tumor angiogenesis and intrinsic drivers of cancer-cell growth. While current targeted therapies rely on identifying ‘specific targets,’ the immune system relies on a broad and diversified repertoire of antibodies to recognize antigens.
New research reports the development and applicability of libraries of immune cells displaying diverse repertoires of CARs that can recognize non-self-antigens and display antigen-dependent clonal expansion. The findings are published in Nature Biomedical Engineering.
Antibody libraries can be constructed based on immunized animals, naturally immunized or infected humans, naïve immune systems, or synthetic sources. With sufficiently high diversity, antibody libraries can generate antibodies against different antigens, including self-non-immunogenic and toxic antigens. For this reason, these libraries are now extensively used in industry and academia.
This technology would allow:
(1) The creation of polyclonal yet defined candidate constructs targeting tumors.
(2) The generation of individual tumor-specific antibodies.
(3) The identification of tumor-specific neo-antigens.
Therefore, the synthetic cell library can extend the scope of both adoptive cell therapy and antibody-display and screening technologies. Considering the evolutionary enrichment properties, the synthetic cell library could be particularly well suited to tumor-xenograft settings and can be extended to other disease models, such as endometriosis and organ fibrosis. This system could be a compelling technology to screen for functional CAR and discover drug candidates and targets.
ارسال به دوستان